Compartmental modelling of the pharmacokinetics of a breast cancer resistance protein

  • Authors:

  • Thomas R. B. Grandjean;Mike J. Chappell;James T. W. Yates;Kevin Jones;Gemma Wood;Tanya Coleman

  • Affiliations:

  • School of Engineering, University of Warwick, Coventry CV4 7AL, UK;School of Engineering, University of Warwick, Coventry CV4 7AL, UK;AstraZeneca R&D, Alderley Park, Macclesfield, SK10 4TG, UK1;AstraZeneca R&D, Alderley Park, Macclesfield, SK10 4TG, UK1;AstraZeneca R&D, Alderley Park, Macclesfield, SK10 4TG, UK1;AstraZeneca R&D, Alderley Park, Macclesfield, SK10 4TG, UK1

  • Venue:
  • Computer Methods and Programs in Biomedicine
  • Year:
  • 2011

Quantified Score

Hi-index 0.00

Visualization

Abstract

A mathematical model for the pharmacokinetics of Hoechst 33342 following administration into a culture medium containing a population of transfected cells (HEK293 hBCRP) with a potent breast cancer resistance protein inhibitor, Fumitremorgin C (FTC), present is described. FTC is reported to almost completely annul resistance mediated by BCRP in vitro. This non-linear compartmental model has seven macroscopic sub-units, with 14 rate parameters. It describes the relationship between the concentration of Hoechst 33342 and FTC, initially spiked in the medium, and the observed change in fluorescence due to Hoechst 33342 binding to DNA. Structural identifiability analysis has been performed using two methods, one based on the similarity transformation/exhaustive modelling approach and the other based on the differential algebra approach. The analyses demonstrated that all models derived are uniquely identifiable for the experiments/observations available. A kinetic modelling software package, namely FACSIMILE (MPCA Software, UK), was used for parameter fitting and to obtain numerical solutions for the system equations. Model fits gave very good agreement with in vitro data provided by AstraZeneca across a variety of experimental scenarios.